Systemic Reluctance: Medical Inertia and the Pharmaceutical Industry’s Influence on Long COVID Treatment

Abstract Despite the global burden of Long COVID, the medical profession has demonstrated a striking reluctance to engage in consistent diagnosis, treatment, and research. This article explores the multifactorial roots…[...]

Read More

Exploring DNA methylation, telomere length, mitochondrial DNA, and immune function in patients with Long-COVID

Andrea Polli, Lode Godderis, Dries S. Martens, et. al., , BMC Medicine volume 23, Article number: 60 (2025) Cite this article Abstract Background Long-COVID is defined as the persistency or development of new symptoms 3 months after the initial SARS-CoV-2…[...]

Read More

🌬️ Idiopathic Dyspnea in Long COVID: Mechanisms, Diagnostics, and Emerging Therapies

🧠 Introduction Idiopathic shortness of breath—dyspnea without a clear structural or functional cause—is a perplexing symptom in many Long COVID patients. Despite normal imaging and pulmonary function tests, individuals report…[...]

Read More